Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount - PLRX News | RalliesPliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount
P
PLRX• Analyst view
- The current average analyst rating on the shares is hold.
- The breakdown of recommendations is no strong buy or buy, 4 hold and 1 sell or strong sell.
- Wall Street's median 12-month price target for Pliant Therapeutics is $2.50, about 140.4% above its August 10 closing price of $1.04.
Outlook and cash runway
- Pliant expects interim data from the FORTIFY trial in 2027.
- The company plans to provide additional detail on its integrin-targeted delivery platform in H2 2026.
- It said cash, cash equivalents and short-term investments are expected to fund operations into H2 2028.
Trial progress and biomarker data
- The company said enrollment in the FORTIFY Phase 1b oncology trial for PLN-101095 is progressing ahead of schedule.
Quarterly results and cost reduction
- Pliant Therapeutics said its Q2 net loss narrowed from the prior year.
- Operating expenses fell sharply after the company discontinued its bexotegrast program and reduced headcount.
- The company reported Q2 net loss of $22.37 million and Q2 operating expenses of $23.86 million.
NRC
•
